HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by NIESTERS, H. G. M. Articles by OSTERHAUS, A. D. M. E. Search for Related Content PubMed PubMed Citation Articles by NIESTERS, H. G. M. Articles by OSTERHAUS, A. D. M. E. Agricola Articles by NIESTERS, H. G. M. Articles by OSTERHAUS, A. D. M. E.

Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy

Department of Virology and *Gastroenterology, University Hospital Rotterdam, Rotterdam, The Netherlands

Corresponding author: Dr H. G. M. Niesters (e-mail: niesters{at}viro.fgg.eur.nl).

Received 15 June 2001; revised version accepted 11 March 2002.

Abstract

A new hepatitis B virus variant selected during lamivudine treatment was detected, in which the methionine (rtM204) in the so-called YMDD motif in the C domain of the catalytic site of the polymerase gene was replaced by a serine (rtM204S). This change simultaneously resulted in a tyrosine-195 into valine variant (sY195V) in the surface protein HBsAg. The detection of this YSDD variant was initially observed, after an increase of HBV DNA levels, by sequencing of amplification products from day 586. A specific RFLP assay was developed that could identify 10% of YSDD-containing variants in the virus pool, which enabled detection of this new variant virus at day 506. However, by cloning several PCR products and sequencing individual recombinant clones, the mutation was first identified at day 477, before a significant increase of HBV DNA was observed in serum. The mutation was followed by a leucine to methionine change at position 180 (rtL180M). The consequences of this mutation for disease management and diagnostic strategies are discussed.

This article has been cited by other articles:

				I. Komla-Soukha and C. Sureau A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles. J. Virol., May 1, 2006; 80(10): 4648 - 4655. [Abstract] [Full Text] [PDF]

				C. Pallier, L. Castera, A. Soulier, C. Hezode, P. Nordmann, D. Dhumeaux, and J.-M. Pawlotsky Dynamics of Hepatitis B Virus Resistance to Lamivudine J. Virol., January 15, 2006; 80(2): 643 - 653. [Abstract] [Full Text] [PDF]

				Z.-Y. Ou, N. Liu, C.-J. Chen, G. Cheng, and Y.-S. He Rapid and Accurate Genotyping of YMDD Motif Variants in the Hepatitis B Virus Genome by an Improved Reverse Dot Blot Method J. Clin. Microbiol., November 1, 2005; 43(11): 5685 - 5689. [Abstract] [Full Text] [PDF]

				S. B. Pai, A. M. Bozdayi, R. B. Pai, T. Beker, M. Sarioglu, A. R. Turkyilmaz, J. Grier, C. Yurdaydin, and R. F. Schinazi Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2618 - 2624. [Abstract] [Full Text] [PDF]

				H. H. Kessler, E. Stelzl, E. Marth, and R. E. Stauber Detection of Mutations in the Hepatitis B Virus Polymerase Gene Clin. Chem., June 1, 2003; 49(6): 989 - 992. [Full Text] [PDF]

				P. Karayiannis Hepatitis B virus: old, new and future approaches to antiviral treatment J. Antimicrob. Chemother., April 1, 2003; 51(4): 761 - 785. [Abstract] [Full Text] [PDF]